View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 25, 2016updated 13 Jul 2022 10:15am

Merck reports positive results form Chinese Phase III TAILOR trial of Erbitux-Folfox combination

Merck has reported that the Chinese Phase III TAILOR study has demonstrated positive results of Erbitux (cetuximab) plus Folfox chemotherapy, compared with Folfox alone in patients with RAS wild-type metastatic colorectal cancer (mCRC).

Merck has reported that the Chinese Phase III TAILOR study has demonstrated positive results of Erbitux (cetuximab) plus Folfox chemotherapy, compared with Folfox alone in patients with RAS wild-type metastatic colorectal cancer (mCRC).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The company stated that the Phase III trial met its primary endpoint of significantly increasing progression-free survival (PFS) in patients with RAS wild-type mCRC treated with Erbitux (cetuximab) plus Folfox chemotherapy, compared with Folfox alone.

Secondary endpoints of the trial include overall survival, best overall response rate, time to treatment failure and rate of curative surgery for liver metastases.

During the trial, all randomised subjects were scheduled to receive treatment until the occurrence of progressive disease (PD) or unacceptable toxicity.

"It is … reassuring that the results reflect those previously observed, and support the indicated first-line use of Erbitux plus FOLFOX in many countries."

The open-label, randomised, controlled, multi-centre trial enrolled 397 patients with RAS wild-type mCRC.

Following the positive response of the trial, Merck is planning to work with relevant authorities to make Erbitux available for patients in China as a first-line treatment for RAS wild-type mCRC patients.

Merck also noted that the clinical benefit that Erbitux provides to RAS wild-type mCRC patients is further reinforced by the secondary endpoint results, which support the superiority shown for PFS.

The safety profile of Erbitux in the TAILOR clinical trial was manageable and similar to that observed in other major trials, with no surprising safety findings.

Both the National Comprehensive Cancer Network in the US and the European Society for Medical Oncology clinical guidelines advocate first-line treatment with Erbitux plus Folfox or Folfiri for patients with RAS wild-type mCRC.

TAILOR study coordinating investigator Shukui Qin said: "We are excited that the TAILOR study is positive and that Erbitux in combination with chemotherapy could become a new first-line treatment option for metastatic colorectal cancer patients in China, once approved.

"It is also reassuring that the results reflect those previously observed, and support the indicated first-line use of Erbitux plus FOLFOX in many countries."

So far, Erbitux has received marketing authorisation in more than 90 countries across the globe.

In Europe, Erbitux is considered as first-line therapy for patients with RAS wild-type mCRC tumours, together with the oxaliplatin-containing regimen Folfox in treatment-naïve patients or with regimens containing irinotecan.

More than 442,000 patients with mCRC have been treated with Erbitux, a IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena